Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.

  title={Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.},
  author={Adriane D. M. Vorselaars and Heleen A. Crommelin and Vera H M Deneer and Bob Meek and Anke M E Claessen and Ruth G M Keijsers and Coline HM van Moorsel and Jan C. Grutters},
  journal={The European respiratory journal},
  volume={46 1},
Inconclusive evidence for the efficacy of infliximab in sarcoidosis hinders the global use of this potentially beneficial drug. To study infliximab efficacy in a clinical setting, we performed a prospective open-label trial in patients refractory to conventional treatment. Patients (n=56) received eight infusions of 5 mg·kg(-1) infliximab. Pulmonary function, disease activity measured by (18)F-fluorodeoxyglucose (FDG) by positron emission tomography (PET) and quality of life were part of the… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 15 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 10 extracted citations

[Lung sarcoidosis: Clinical features and therapeutic issues].

La Revue de medecine interne • 2016
View 3 Excerpts
Highly Influenced

Cough in sarcoidosis patients.

Respiratory physiology & neurobiology • 2018
View 2 Excerpts

[Current Therapeutic Approaches to Sarcoidosis].

Deutsche medizinische Wochenschrift • 2017
View 2 Excerpts

Infliximab or biosimilars in sarcoidosis; to switch or not to switch?

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG • 2016
View 3 Excerpts


Publications referenced by this paper.
Showing 1-10 of 42 references

Health-related quality of life in sarcoidosis

IH Korenromp, MA vandeLaar
Curr Opin Pulm Med • 2014

Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment

HN van Rijswijk, AD Vorselaars, HJ Ruven
Expert Opin Orphan Drugs • 2013

Similar Papers

Loading similar papers…